All In Biotech

Drug Trial Radar · NCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

May 16, 2023

Primary completion

Jun 11, 2027

Study completion Apr 10, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • PaclitaxelDrug

    80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.

  • IrinotecanDrug

    180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.

  • PembrolizumabBiological

    200 mg IV infusion, administered every Q3W up to 35 infusions.

  • MK-4830Biological

    800 mg IV infusion, administered Q3W up to 35 infusions.

  • LenvatinibDrug

    20 mg oral administration every day.

  • Sacituzumab tirumotecanBiological

    4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.

  • AntihistamineDrug

    Administered per product label.

  • H2 Receptor AntagonistDrug

    Administered per product label.

  • Acetaminophen (or equivalent)Drug

    Administered per product label.

  • Dexamethasone (or equivalent)Drug

    Administered per product label.

  • Steroid Mouthwash (dexamethasone or equivalent)Drug

    Administered per product label.

  • Supportive care measuresDrug

    Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
  2. Number of Participants Who Experienced an Adverse Event (AE) During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
  3. Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
  4. Objective Response Rate (ORR)Time frame: Up to approximately 48 months

Locations

58 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)

    Tucson, Arizona · Recruiting

  • UCLA Hematology/Oncology - Santa Monica ( Site 4905)

    Los Angeles, California · Recruiting

  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925)

    East Syracuse, New York · Recruiting

  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907)

    New York, New York · Completed

  • UPMC Hillman Cancer Center-UPMC ( Site 4904)

    Pittsburgh, Pennsylvania · Recruiting

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300)

    São Paulo, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 4303)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hospital Nossa Senhora da Conceição ( Site 4301)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • FALP-UIDO ( Site 4400)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Oncología de Precisión-Oncology ( Site 4404)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Clínica las Condes ( Site 4403)

    Santiago, Region M. de Santiago, Chile · Completed

  • Clínica UC San Carlos de Apoquindo ( Site 4405)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Anhui Provincial Hospital ( Site 3501)

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer hospital-Digestive Oncology ( Site 3500)

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University ( Site 3516)

    Xiamen, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510)

    Xinxiang, Henan, China · Recruiting

  • Henan Cancer Hospital ( Site 3518)

    Zhengzhou, Henan, China · Recruiting

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506)

    Huai'an, Jiangsu, China · Recruiting

  • Shanghai Chest Hospital-Esophageal surgery department ( Site 3513)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511)

    Hangzhou, Zhejiang, China · Recruiting

  • Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 4804)

    Berlin, Germany · Completed

  • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 4807)

    Erdgeschoss, Free and Hanseatic City of Hamburg, Germany · Recruiting

  • Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 4801)

    Frankfurt am Main, Hesse, Germany · Completed

  • Universitaetsklinikum Duesseldorf ( Site 4802)

    Düsseldorf, North Rhine-Westphalia, Germany · Completed

  • Ospedale San Raffaele-Oncologia Medica ( Site 3202)

    Milan, Italy · Recruiting

  • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Site 3201)

    Milan, Italy · Completed

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 3207)

    Meldola, Emilia-Romagna, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3200)

    Milan, Lombardy, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Pisana ( Site 3206)

    Pisa, Tuscany, Italy · Recruiting

  • Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 3203)

    Padova, Veneto, Italy · Recruiting

  • Aichi Cancer Center ( Site 3702)

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East ( Site 3701)

    Kashiwa, Chiba, Japan · Recruiting

  • Saitama Prefectural Cancer Center ( Site 3703)

    Kitaadachi-gun, Saitama, Japan · Recruiting

  • Shizuoka Cancer Center ( Site 3704)

    Nagaizumi-cho,Sunto-gun, Shizuoka, Japan · Recruiting

  • National Cancer Center Hospital ( Site 3700)

    Chuo-ku, Tokyo, Japan · Recruiting

  • Oslo universitetssykehus, Radiumhospitalet ( Site 4501)

    Oslo, Norway · Recruiting

  • National University Hospital ( Site 3800)

    Singapore, South West, Singapore · Recruiting

  • Asan Medical Center-Department of Oncology ( Site 3901)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)

    Seoul, South Korea · Recruiting

  • Hôpitaux Universitaires de Genève (HUG) ( Site 4702)

    Geneva, Canton of Geneva, Switzerland · Recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.